Drugs Made In America Acquisition Corp.
Business
Drugs Made In America Acquisition Corp. is a blank check company incorporated in the Cayman Islands that raised capital in its initial public offering to identify and acquire a target business. The company has no operations and holds cash in a trust account, with a deadline to complete an initial business combination. Management intends to focus on artificial intelligence, pharmaceutical, or other innovation-driven businesses in the United States, with preliminary interest in an enterprise technology platform. The company has extended its business combination deadline, subject to sponsor funding of monthly extensions.
Summary from 10-K filed 2026-04-15
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 |
|---|---|---|
| General and administrative costs | 3 | |
| Loss from operations | −3 | |
| Interest earned on cash and investments held in Trust Account | 9 | |
| Total other income | 9 | |
| NET INCOME (LOSS) | 6 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2024 2024-05-31 |
|---|---|---|---|---|
| Cash | 6,137 | 1,351 | — | |
| Prepaid expenses and other current assets | 6,054 | 3,640 | — | |
| Total current assets | 12,191 | 4,991 | — | |
| Cash and investments held in Trust Account | 240 | — | — | |
| Deferred offering costs | — | 545,833 | — | |
| Total non-current assets | 240 | 545,833 | — | |
| TOTAL ASSETS | 240 | 550,824 | — | |
| Accounts payable and accrued expenses | 222,184 | 77,280 | — | |
| Accrued offering costs | 153,988 | 56,065 | — | |
| Total current liabilities | 376,172 | 795,669 | — | |
| Deferred underwriting fee payable | 7 | — | — | |
| Total non-current liabilities | 7 | — | — | |
| Total Liabilities | 7 | 795,669 | — | |
| Commitments and Contingencies (Note 6) | — | — | — | |
| Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of $10.43 and $0 per share as of December 31, 2025 and 2024, respectively | 240 | — | — | |
| Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding as of December 31, 2025 and 2024 | — | — | — | |
| Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; 10,717,143 and 9,857,143 shares issued and outstanding, excluding 23,000,000 and 0 shares subject to redemption as of December 31, 2025 and 2024, respectively(1) | 1,072 | 986 | — | |
| Additional paid-in capital | — | 34,014 | — | |
| Accumulated deficit | −7 | −279,845 | — | |
| Total Shareholders Deficit | −7 | −244,845 | — | |
| TOTAL LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION AND SHAREHOLDERS DEFICIT | 240 | 550,824 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 |
|---|---|---|
| Payment of operating costs through promissory note | 141,976 | |
| Share issuance expense | 2 | |
| Prepaid expenses | −6,054 | |
| Accounts payable and accrued expenses | 144,904 | |
| Net cash used in operating activities | −539,187 | |
| Investment of cash into Trust Account | −231 | |
| Net cash used in investing activities | −231 | |
| Proceeds from sale of Units, net of underwriting discounts paid | 229 | |
| Proceeds from issuance of Class B ordinary shares to Sponsor | — | |
| Proceeds from promissory note - related party | — | |
| Proceeds from sale of Private Placement Units | 3 | |
| Expenses paid by Sponsor under share subscription receivable | 540,778 | |
| Repayment of promissory note - related party | −900,000 | |
| Payment of offering costs | 3,195 | |
| Net cash provided by financing activities | 232 | |
| Net Change in Cash | 4,786 | |
| Share subscription receivable | 1 | |
| Offering costs included in equity | 848,201 | |
| Offering costs included in accrued offering costs | 94,516 | |
| Deferred offering costs paid through promissory note related party | 204,000 | |
| Accretion and remeasurement of redeemable ordinary shares to redemption value | 22 | |
| Deferred underwriting fee payable | 7 | |
| Offering costs paid via prepaid expense | 3,640 | |
| Prepaid services contributed by Sponsor through promissory note related party | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Drugs Made In America Acquisition Corp.'s CIK number?
Drugs Made In America Acquisition Corp.'s SEC CIK number is 0002028614 (2028614). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Drugs Made In America Acquisition Corp.'s SEC filings?
All of Drugs Made In America Acquisition Corp.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.